Member Info for fatprofits

Steve, good fortune with your holding.

It can be ruinous for longer term capital returns.

If your investments can generate decent capital growth,

it gives an option of occasionally selling a small % to boost income,

if needed.

The above is for discussion purposes Only - everyone will have unique

personal circumstances etc.

UKX off approx 1.4%, net off the divi, not a terrible performance on the close.

Overseas earners also disproportionately hit today on FX moves.

Throw rising bond yields in to the mix etc...

Https://www.woodlockhousefamilycapital.com/post/cutting-dividends-to-create-value

Novo Nordisk.

Up over 24 X over the last 20 years, extraordinary.

For anyone who saw Andrew present, Emma does not convey
the same confidence imv.

Now to be fair Andrew's tenure was marred by a number of issues,

but his scientific background shone through.

I would Not expect EW to depart anytime soon, certainly not pre split,

barring something left field.

GSK do not do quick CEO turnover and even though not a fan

it's significantly too soon to judge the her performance.

Well the point is comparitve return.

Unilever traded under £5 a share in Feb 1991.

Yes, however look at ULVR v GSK over 30 years, 25, years, 20 years, 15 years...

* veracity

Fats needs a different spell checker!.

Really, seriously??.

Not necessarily questioning the varsity of that

but find it a little incredulous.

But without the divi obvs.

Just over 15 pence a share reduction on the holding cost.

Was it worth it?, as I'm shielding due to underlying health conditions
I don't have a great deal to do atm! ).

Average @ 12.432 - inclusive of commission and stamp duty.

Poker, if consensus is incorrect, there are some very nasty % falls

to come on many cyclicals.

Made this point recently but worth underlining.

To be fair to GSK they spelled out and underlineed in red

the likely pandemic hit on the 2020 Q2 update.

May be some PI's don't read statements, but its all there in black and white.

Also assuming the FY 2021 guidance was reduced largely because of the Covid-19 pandemic

dragging on for longer than anticipated - that may have been explicitly stated

in FY statement, would need to check.

Just bought back the BATS shares traded yesterday.

Missed SN this morning unfortunately, under£ 14.50 looked attractive.

Looking to buy some AZN sold yesterday lower down, but nothing doing atm.

Poker, that's not what cyclicals say!!.

Obvs market consensus could be wrong.

Look at the RYA SP as one example of the market betting on a rapid resumption
of a normal, or near normal operating environment.

For sentiment at least, any good news on continuing reduction

in case numbers and a resumption of normality should be highly positive.

GSK has made it crystal clear that 2021 FY guidance

is predicated on healthcare systems returning to normal in H2.

They have explicitly stated this.

On fundamentals, the pandemic dragging on is hideously expensive for GSK
on lower vaccine uptake rates.

Now you could make a case that's in the price.

While I rarely make a decision on buying/selling based on

a bb post, Toff made a good case for selling before the XD

and only fair to say it was a factor in my decision to sell -

particularly as had observed a similar XD move previously.

Toff's posting was an apt reminder of this.

So thank you and good call.